|
19 May 2008 |
Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder with Tengion Neo-Bladder Replacement(TM)
|
|
16 May 2008 |
OncoGenex reports updated survival data on OGX-011 in a second-line chemotherapy trial for patients with prostate cancer
|
|
15 May 2008 |
FDA Places Geron’s GRNOPC1 IND on Clinical Hold
|
|
13 May 2008 |
AVI BioPharma Announces Significant Advance in the Potential Treatment of Ebola and Marburg Virus Infections
|
|
12 May 2008 |
Argos Therapeutics Initiates Phase 2 Proof-of-Concept Trial for its Arcelis(TM) Personalized Immunotherapy Platform in HIV
|
|
09 May 2008 |
Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
|
|
09 May 2008 |
Osiris and NuVasive Enter into Definitive Agreement for Osteocel(R)
|
|
08 May 2008 |
Osiris Receives Approval for Use of Prochymal(TM) Under FDA Expanded Access Treatment Program
|
|
07 May 2008 |
FDA and the Paul Ehrlich Institute (Germany) Approve Pluristem’s Regulatory Submissions in Support of a Phase I/II Clinical Trial Utilizing PLX-PAD for Peripheral Artery Disease
|
|
05 May 2008 |
MOLOGEN AG receives approval for clinical study with cancer drug MGN1703
|
|
02 May 2008 |
Celgene Cellular Therapeutics Announces Clinical Transplant of Human Placenta-Derived Stem Cells
|
|
30 Apr 2008 |
Topigen reports progess toward clinical trials for TPI 1100 at Rnai World CongressTopigen reports progess toward clinical trials for TPI 1100 at Rnai World Congress
|
|
29 Apr 2008 |
Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172
|
|
28 Apr 2008 |
Alnylam and Collaborators at MIT Publish Research on the Discovery of 'Lipidoids', a Novel Class of Lipid-Based Molecules for the Delivery of RNAi Therapeutics
|
|
28 Apr 2008 |
Targeted Genetics Announces Data From First Gene Therapy Trial for Leber's Congenital Amaurosis in New England Journal of Medicine
|
|
25 Apr 2008 |
FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
|
|
24 Apr 2008 |
ReNeuron announces further pre-clinical data with its ReN003 programme for diseases of the retina
|
|
23 Apr 2008 |
Lorus initiates development program exploring novel route of administration for LOR-2040
|
|
21 Apr 2008 |
Calando Receives FDA Approval for Phase I Clinical Trial Using a Targeted siRNA Nanoparticle Therapeutic
|
|
18 Apr 2008 |
Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis
|
|
17 Apr 2008 |
GlaxoSmithKline and Regulus Therapeutics form strategic alliance to develop microRNA targeted therapeutics to treat inflammatory diseases
|
|
16 Apr 2008 |
Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
|
|
16 Apr 2008 |
Aldagen Announces Initiation of ALD-101 Phase III Trial for Improving Cord Blood Transplants in Pediatric Patients With Inherited Metabolic Diseases
|
|
14 Apr 2008 |
Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain
|
|
09 Apr 2008 |
Alnylam Initiates Phase II Trial to Evaluate Safety and Tolerability of ALN-RSV01 in Adult Lung Transplant Patients Naturally Infected with Respiratory Syncytial Virus (RSV) Infection
|
